ASCO GU 2019
ASCO GU 2019: Outcomes of Patients with Metastatic Clear Cell RCC Treated with Second Line VEGFR-TKI After First Line Immune Checkpoint Inhibitor
ASCO GU 2019: Pembrolizumab in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer
ASCO GU 2019: Questions and Lessons Moving Forward from CARMENA: Which Treatment First? Surgeon’s Perspective
- Remove a large, potentially immunosuppressive tumor that is a potential source of metastases and paraneoplastic syndromes
- Palliate local symptoms of pain or bleeding that could complicate/interrupt systemic therapy
- Obtain accurate pathologic subtyping to guide therapy
- Should never be done to induce spontaneous metastatic tumor regression (it is a real event, but rare)
ASCO GU 2019: Questions and Lessons Moving Forward from CARMENA: Which Treatment First? Medical Oncologist’s Perspective
ASCO GU 2019: Informing the Decision Using Data Science
To begin, the only Level 1 evidence supporting the oncologic efficacy PN compared to RN is the EORTC study by van Poppel et al. (EU 2007). However, it was underpowered and had significant cross-over.